检索结果-南通市图书馆

Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and metaanalysis

引用

World Journal of Clinical Cases 2021年第3期9卷 581-601页

作者： Yu-Qiong Xu Xiang Long Ming Han Ming-Qiang Huang Jia-Fa Lu Xue-Dong Sun Wei Han Department of Emergency Medicine Shenzhen University General HospitalShenzhen University Clinical Medical AcademyShenzhen 518000Guangdong ProvinceChina Department of Respiratory and Critical Care Medicine Peking University Shenzhen HospitalShenzhen 518000Guangdong ProvinceChina

BACKGROUND Lung cancer is a major cause of death among patients,and non-small cell lung cancer(NSCLC)accounts for more than 80%of all lung cancers in many *** To evaluate the clinical benefit(CB)of COX-2 inhibitors in patients with advanced NSCLC using systematic *** We searched the six electronic databases up until December 9,2019 for studies that examined the efficacy and safety of the addition of COX-2 inhibitors to chemotherapy for *** survival(OS),progression free survival(PFS),1-year survival rate(SR),overall response rate(ORR),CB,complete response(CR),partial response(PR),stable disease(SD),and toxicities were measured with more than one outcome as their *** and random effects models were used to calculate risk estimates in a *** publication bias was calculated using Egger’s linear regression *** analysis was performed using R *** The COX-2 inhibitors combined with chemotherapy were not found to be more effective than chemotherapy alone in OS,progression free survival,1-year SR,CB,CR,and ***,there was a difference in overall response rate for patients with advanced *** a subgroup analysis,significantly increased ORR results were found for celecoxib,rofecoxib,first-line treatment,and *** adverse events,the increase in COX-2 inhibitor was positively correlated with the increase in grade 3 and 4 toxicity of leukopenia,thrombocytopenia,and cardiovascular *** COX-2 inhibitor combined with chemotherapy increased the total effective rate of advanced NSCLC with the possible increased risk of blood toxicity and cardiovascular events and had no effect on survival index.

关键词： Non-small cell lung cancer COX-2 survival progression free survival Systematic review Randomized controlled trials

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer

引用

World Journal of Clinical Cases 2020年第22期8卷 5564-5575页

作者： Yang-Yang Ma Yin Leng Yan-Li Xing Hong-Mei Li Ji-Bing Chen Li-Zhi Niu Central Laboratory Affiliated Fuda Cancer HospitalJinan UniversityGuangzhou 510665Guangdong ProvinceChina Department of Oncology Affiliated Fuda Cancer HospitalJinan UniversityGuangzhou 510665Guangdong ProvinceChina Department of Interventional Radiology Affiliated Fuda Cancer HospitalJinan UniversityGuangzhou 510665Guangdong ProvinceChina

BACKGROUND Locally advanced pancreatic cancer(LAPC)is a common malignant digestive system tumor that ranks as the fourth leading cause of cancer-related death in the *** prognosis of LAPC is poor even after standard *** electroporation(IRE)is a novel ablative strategy for *** studies have confirmed the safety of *** date,no prospective studies have been performed to investigate the therapeutic efficacy of conventional gemcitabine(GEM)plus concurrent *** To compare the therapeutic efficacy between conventional GEM plus concurrent IRE and GEM alone for *** From February 2016 to September 2017,a total of 68 LAPC patients were treated with GEM plus concurrent IRE(n=33)or GEM alone(n=35).Overall survival(OS),progression free survival(PFS),and procedure-related complications were compared between the two *** analyses were performed to identify any prognostic *** There were no treatment-related *** technical success rate of IRE ablation was 100%.The GEM+IRE group had a significantly longer OS from the time of diagnosis of LAPC(19.8 mo vs 9.3 mo,P<0.0001)than the GEM alone *** GEM+IRE group had a significantly longer PFS(8.3 mo vs 4.7 mo,P<0.0001)than the GEM alone *** volume less than 37 cm3 and GEM plus concurrent IRE were identified as significant favorable factors for both the OS and *** Gemcitabine plus concurrent IRE is an effective treatment for patients with LAPC.

关键词： Irreversible electroporation Gemcitabine Locally advanced pancreatic cancer Overall survival progression free survival Prognostic factors

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Clinical outcomes of people living with human immunodeficiency virus(HIV)with diffuse large B-cell lymphoma(DLBCL)in Shanghai,China

引用

Chinese Medical Journal 2020年第23期133卷 2796-2802页

作者： Jian-Jun Sun Li Liu Jiang-Rong Wang Yin-Zhong Shen Tang-Kai Qi Zhen-Yan Wang Yang Tang Wei Song Jun Chen Ren-Fang Zhang Department of Infection and Immunity Shanghai Public Health Clinical CenterFudan UniversityShanghai 201508China

Background:Numerous studies have focused on lymphoma among patients infected with human immunodeficiency virus(HIV).However,little is known about the treatment options and survival rate of lymphoma in the Chinese people living with HIV(PLHIV).Our study aimed to investigate the prognosis and compare outcome of dose-adjusted etoposide,prednisone,vincristine,cyclophosphamide,doxorubicin,and rituximab(DA-EPOCH-R)with standard cyclophosphamide,doxorubicin,vincristine,prednisone and rituximab(R-CHOP)as front line therapy for PLHIV with diffuse large B-cell lymphoma(DLBCL)receiving modern combined antiretroviral therapy(cART).Methods:A retrospective analysis evaluating PLHIV with DLBCL was performed in Shanghai Public Health Clinical Center from July 2012 to September *** demographic and clinical data were collected,and overall survival(OS)and progression-free survival(PFS)analyses of patients receiving R-CHOP or DA-EPOCH-R therapy were performed by Kaplan-Meier ***,a Cox multiple regression model was constructed to identify related factors for ***:A total of 54 eligible patients were included in the final analysis with a median follow-up of 14 months(interquartile range[IQR]:8-29 months).The proportion of high international prognostic index(IPI)patients was much larger in the DA-EPOCH-R group(n=29)than that in the R-CHOP group(n=25).The CD4 cell counts and HIV RNA levels were not significantly different between the two *** 2-year OS for all patients was 73%.However,OS was not significantly different between the two groups,with a 2-year OS rate of 78%for the DA-EPOCH-R group and 66%for the R-CHOP *** an IPI greater than 3 was associated with a decrease in OS,with a hazard ratio of *** occurrence of grade 3 and 4 adverse events of chemotherapy was not significantly different between the two ***:Outcomes of R-CHOP therapy do not differ from those of DA-EPOCH-R *** HIV-related factors were found to be assoc

关键词： Diffuse large B-cell lymphoma HIV infection Overall survival progression free survival

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Clinical significance of chromosomal abnormalities detected by interphase fluorescence in situ hybridization in newly diagnosed multiple myeloma patients

引用

Chinese Medical Journal 2011年第19期124卷 2981-2985页

作者： HU Yu CHEN Lei SUN Chun-yan SHE Xiao-mei AI Li-sha QIN You Institute of Hematology Union Hospital Tongji Medical CollegeHuazhong University of Science and Technology Wuhan Hubei 430022 China

Background Chromosome 13q14 deletion （del13q14）, chromosome 1q21 gain （amp1q21） and chromosome 17p13 deletion （del17p13） are the most frequent chromosomal aberrations in multiple myeloma （MM）. They play an important role in prognosis. The aim of this study was to investigate the clinical significance of the chromosomal changes in Chinese MM *** Interphase fluorescence in situ hybridization （FISH） on bone marrow （BM） cells was performed in 72 enrolled MM patients. Relationships between chromosomal abnormalities and clinical features, response to therapies and prognosis were *** As a result of interphase FISH, 77.8% （56/72） patients had chromosome changes. The incidences of each probe were RB1 51.4% （37/72）, D13S319 47.2% （34/72）, 1q21 45.8% （33/72） and p53 22.2% （12/72）. Osteolytic lesion,BM plasma cells index, serum calcium and serum M component were significantly correlated to del13q14. BM plasma cells and hemoglobin were correlated to amp1q21. Serum lactate dehydrogenase （LDH） was correlated with *** with del13q14 treated with bortezomib had a notably higher overall response rate than the patients treated with traditional chemotherapies （93% vs. 65%, P=0.048）. Patients carrying amp1q21 or/and del17p13 did not achieve satisfactory response to bortezomib. The median progression-free survival （PFS） for patients with amp1q21 was 5 months and patients without amp1q21 got 9-month PFS （P=0.001）. The median PFS for patients with del13q14 was 5 months （vs. 8 months, P=0.026）. The median PFS for patients with del17p13 was 3 months （vs. 8 months, P=0.002）.Patients with β2-microglobulin 〉5.5 mg/L also had a worse outcome, whose median PFS was 5 months （vs. 8 months,P=0.016）.Conclusions The prevalence of chromosomal abnormalities of MM patients was similar in Chinese and Caucasian people. Genetic changes were associated with patients＇ responses to therapies and prognosis.

关键词： multiply myeloma fluorescence in situ hybridization cytogenetics prognosis progression free survival

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Treatment free Intervals after Subsequent Chemotherapy Lines in Recurrent Ovarian Cancer

引用

Journal of Cancer Therapy 2021年第6期12卷 346-357页

作者： Hanna Sallinen Vivi Rintanen Leea Keski-Nisula Maarit Anttila Department of Gynecology and Obstetrics Kuopio University Hospital Kuopio Finland Department of Health Sciences Clinical Medicine University of Eastern Finland Kuopio Finland

Aim: Despite recent advances in the treatment of ovarian cancer, recurrence of the disease is still frequent. This study evaluated whether multiple lines of chemotherapy have impact on overall survival (OS), progression free survival (PFS) or on treatment free intervals (TFIs) after serial chemotherapy lines in recurrent settings. Methods: A total of 189 patients with ovarian cancer (including fallopian tube and primary peritoneal cancer), who were treated in Kuopio University Hospital in Finland during 2009-2014, were enrolled. The medical files of these patients were retrospectively reviewed. Results: Median OS and PFS were significantly higher at the time of the first relapse compared to subsequent relapses (p platinum sensitive, semi-sensitive and platinum resistant patients. The total amount of TFI times during the whole follow-up time was significantly reduced in those patients that received at least one form of aggressive c

关键词： Ovarian Cancer Chemotherapy Treatment free Interval Overall survival progression free survival Aggressive Care

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy of percutaneous ethanol injection in the adjuvant treatment of hepatocellular carcinoma after TACE

引用

The Chinese-German Journal of Clinical Oncology 2009年第2期8卷 69-72页

作者： Mingzhi Hao Hailan Lin Youhong Shen Linan Tang Ruoyuan Yan Jianxiong Zheng Ojzhong Chen Jing Chen Zhougui Wu Department of Interventional Radiology Fujian Provincial Tumor Hospital Fuzhou 350014 China Department of Ultrasound Fujian Provincial Tumor Hospital Fuzhou 350014 China

Objective： To evaluate the efficacy of percutaneous ethanol injection （PEI） in the adjuvant treatment of hepatocellular carcinoma （HCC） after transcatheter arterial chemoembolization （TACE） by primary end points of time to progress （TTP）. Methods： The study population consisted of 73 consecutive patients with inoperable HCC （China Classification System IIN liB）. Among them, 22 patients were treated with TACE and PEI （experimental group）, and the rest 51 were treated only with TACE （control group）, and then the time to progress （TTP） and overall survival （OS） of these two groups were analyzed. Results： The median TTP was 10 months [95% confidence interval （CI）, 7.9-12.1 months] in experimental group and 6 months （95% CI, 4.7-7.3 months） in control group. The 3-month,6-month, and 1-year progression free survival （PFS） rates were respectively 77.3%, 63.6%, and 48.1% in experimental group, and 76.5%, 42.15%, and 24.8% in control group. The TTP of experimental group was significantly longer than that of control group （P 〈 0.05）. The median survival period was 17 months [95% confidence interval （CI）, 11-23 months] of experimental group and 12 months （95% CI, 10-14 months） of control group （P 〉 0.05）. Conclusion： Compared with single TACE, the combination of TACE and PEI can obviously postpone disease progress and prolong survival of HCC patients.

关键词： carcinoma hepatocellular chemoembolization therapeutic ethanol time to progress progression free survival postembolization syndrome

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：